2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 21:42, 10 December 2023
, 10 December 2023→Clinical Trials
| Line 210: | Line 210: | ||
!Clinical Trial | !Clinical Trial | ||
!Design | !Design | ||
(dosage is per day, 2x means twice per day) | |||
!Participants | !Participants | ||
!Outcome | !Outcome | ||
| Line 226: | Line 227: | ||
|[[RCT]], 10 weeks | |[[RCT]], 10 weeks | ||
*placebo (n=12) | *placebo (n=12) | ||
*250 mg | *250 mg (n=13) | ||
| | | | ||
*25 postmenopausal women with prediabetes | *25 postmenopausal women with prediabetes | ||
| Line 238: | Line 239: | ||
|[[RCT]], 6 weeks | |[[RCT]], 6 weeks | ||
*placebo (n=12) | *placebo (n=12) | ||
*300 mg | *300 mg (n=12) | ||
*600 mg | *600 mg (n=12) | ||
*1200 mg | *1200 mg (n=12) | ||
| | | | ||
*48 young and middle-aged recreationally trained runners | *48 young and middle-aged recreationally trained runners | ||
| Line 266: | Line 267: | ||
*placebo (n=15) | *placebo (n=15) | ||
*1250 mg | *1250 mg (n=16) | ||
| | | | ||
*31 healthy adult men and women | *31 healthy adult men and women | ||
| Line 307: | Line 308: | ||
* placebo (n=31) | * placebo (n=31) | ||
* | * 300 mg (n=31) | ||
| | | | ||
* 66 healthy subjects | * 66 healthy subjects | ||
| Line 333: | Line 334: | ||
|{{pmid_text|35182418}} | |{{pmid_text|35182418}} | ||
|[[RCT]], 2 weeks | |[[RCT]], 2 weeks | ||
* | *1000 mg MIB-626 | ||
* | *2x1000 mg MIB-626 | ||
*placebo | *placebo | ||
| | | | ||
| Line 349: | Line 350: | ||
|{{pmid_text|36740954}} | |{{pmid_text|36740954}} | ||
|[[RCT]], 4 weeks | |[[RCT]], 4 weeks | ||
* | *2x500 mg/day MIB-626 | ||
*placebo | *placebo | ||
| | | | ||
| Line 366: | Line 367: | ||
* placebo (n=17) | * placebo (n=17) | ||
* 2x125 mg | * 2x125 mg (n=17) | ||
| | | | ||
| Line 380: | Line 381: | ||
* placebo | * placebo | ||
* 250 mg | * 250 mg | ||
| | | | ||
* male patients with diabetes | * male patients with diabetes | ||
| Line 397: | Line 398: | ||
* no NMN (n=10) | * no NMN (n=10) | ||
* 800 mg | * 800 mg (n=9) | ||
| | | | ||
* 19 mild hypertensive adults | * 19 mild hypertensive adults | ||